Regulatory Approach for Biosimilars

Asian Biosimilar 2018 will provide an excellent opportunity to the scientists, partners and pharma leaders from Biopharmaceutical and Biotechnology industries to discuss and learn about the regulatory competencies required for Biosimilars and Biologics.This track includes: Licensing of biosimilars, Biosimilars regulation, Biosimilar Patents , BLA filing for biosimilars, Regulatory prospects of BRIC countries, a paradigm of traditional generics to biosimilars, Biowaiver approval for Biosimilars.
Approximately 20% of the biologics and biosimilars in the  worldwide R&D pipelines are facing challenges to fall in line with the regulatory guidelines..

  • Regulatory prospects of BRIC countries
  • Licensing of biosimilars
  • BLA filing for biosimilars
  • A paradigm of traditional generics to biosimilars
  • Patent disputes and litigations
  • Generic Biosimilars
  • Critical regulatory issues

Related Conference of Regulatory Approach for Biosimilars

June 06-07, 2018

International Conference & B2B on Pharma Research and Development

Philadelphia, Pennsylvania, USA
June 27-28, 2018

4thInternational Conference on Drug Discovery, Designing Chemistry and Development

Vancouver, British Columbia, Canada
August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
November 15-16, 2018

14th International Conference on Generic Drugs and Biosimilars

Frankfurt, Germany
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands

Regulatory Approach for Biosimilars Conference Speakers

Recommended Sessions

Related Journals

Are you interested in